Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis

Cell Reports(2024)10.1016/j.celrep.2024.114431Source: DataRank Database

Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis is a research paper published in Cell Reports (2024). On theSindex it has a DataRank of 0. It has been cited 15 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access15 citations

Download PDF

Cite:

Linked data & code

geo rrid

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 2.43)OA: goldTopics (49)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (15)

Ka-wing Fong ORCID,Fengyi Mao ORCID,Ruixin Wang ORCID,Derek B. Allison ORCID,Dana Napier

Live enrichment

PubMed:38968071 PMC:PMC11334074 OpenAlex:https://openalex.org/W4400318393

American Cancer Society

Grant: IRG 22-152-34

National Institute of General Medical Sciences

Grant: P20GM121327

NIH

Grant: R01 CA196634

Markey Cancer Center, University of Kentucky

Grant: P30CA177558

NCI NIH HHS

Grant: R03 CA256230

NCI NIH HHS

Grant: R01 CA157429

NCATS NIH HHS

Grant: KL2 TR001996

Eastern Kentucky University

FWCI

2.43

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

goldLicense: cc-by-nc

journalhttps://doi.org/10.1016/j.celrep.2024.114431

publisherhttps://doi.org/10.1016/j.celrep.2024.114431

publisherhttps://api.elsevier.com/content/article/PII:S2211124724007605?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211124724007605?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38968071

Fields of Study

Protein Degradation and InhibitorsChromatin Remodeling and CancerUbiquitin and proteasome pathways

MeSH Terms

DocetaxelBromodomain Containing ProteinsPolo-Like Kinase 1AnimalsAzepinesHumansMaleMice, NudeMitosisNuclear ProteinsPhosphorylationProstatic NeoplasmsProto-Oncogene ProteinsRepressor ProteinsTranscription FactorsTriazolesCDC2 Protein KinaseProtein Serine-Threonine KinasesCell Cycle ProteinsDrug Resistance, NeoplasmCell Line, TumorProteasome Endopeptidase ComplexMiceProteolysis

Keywords

PLK1MitosisCancer researchPhosphorylationProstate cancerCancerDegradation (telecommunications)BRD4Cell biologyProstateChemistryBiologyMedicineInternal medicineBiochemistryCell cycleComputer scienceDNAApc/c(cdh1)Cp: Molecular BiologyCp: CancerBet Inhibitor Resistance

Sustainable Development Goals

SDG 0: Good health and well-being

Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis

FAIR Checklist

Authors (15)

Funding (8 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)